Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
nu Osinusi, MD, Vice President, Clinical Development, Virology at Gilead Sciences. “Building on decades of experience responding to serious infectious diseases, our teams are working alongside partners with focus and purpose to support the response to this outbreak.”
June 12, 2026